Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
12:16pm, Friday, 08'th May 2026
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Amneal Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 07'th May 2026
‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:45pm, Wednesday, 29'th Apr 2026
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?
10:57am, Wednesday, 29'th Apr 2026
The consensus price target hints at a 34.8% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?
10:52am, Wednesday, 29'th Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
10:43am, Wednesday, 29'th Apr 2026
Here is how Alignment Healthcare (ALHC) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
10:42am, Wednesday, 29'th Apr 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amneal 2026-2027 Upside From Biosimilars Scale
02:06pm, Tuesday, 28'th Apr 2026
AMRX targets 2027 upside through biosimilars scale, new complex launches, and Specialty recovery after 2026 Rytary erosion pressure.
AMRX Growth Drivers: Generics, Biosimilars, and Crexont
01:27pm, Tuesday, 28'th Apr 2026
Amneal leans on generics stability, biosimilar launches, and Crexont growth as 2026 guidance points to higher EBITDA and EPS despite Specialty headwinds.
AMRX Valuation: What 1.69x Sales Means for Investors
01:27pm, Tuesday, 28'th Apr 2026
Amneal trades at 1.69x sales, below sector benchmarks, as investors weigh raised 2026 profit guidance against Specialty pressure and launch execution.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
10:46am, Monday, 27'th Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
10:33am, Thursday, 23'rd Apr 2026
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 23'rd Apr 2026
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
03:30pm, Wednesday, 22'nd Apr 2026
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
08:21am, Wednesday, 22'nd Apr 2026
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.21 per share a year ago.
